首页> 外国专利> Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome

Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome

机译:M1 / M4毒蕈碱激动剂(Sabcomeline)的单药和联合疗法治疗前驱综合征。

摘要

The invention relates to the use of a functional muscarinic M1/M4 agonist or a pharmaceutically acceptable salt thereof to treat prodromal syndrome and in the manufacture of a medicament for the treatment of prodromal syndrome, and to a method of treatment of prodromal syndrome using a functional muscarinic M1/M4 agonist or a pharmaceutically acceptable salt thereof. It also relates to the use of a pharmaceutical composition comprising a functional muscarinic M1/M4 agonist or a pharmaceutically acceptable salt thereof, and at least one cholinergic agent and/or at least one non-cholinergic agent for the treatment of prodromal syndrome, and to a method of treatment of prodromal syndrome by administration of a such a pharmaceutical composition.
机译:功能性毒蕈碱型M1 / M4激动剂或其药学上可接受的盐本发明涉及功能性毒蕈碱型M1 / M4激动剂或其药学上可接受的盐在治疗前驱综合症中的用途以及在制备用于治疗前驱综合症的药物中的用途,并涉及使用功能性毒蕈碱治疗性前驱综合症的方法毒蕈碱M1 / M4激动剂或其药学上可接受的盐。本发明还涉及包含功能性毒蕈碱型M1 / M4激动剂或其药学上可接受的盐以及至少一种胆碱能药和/或至少一种非胆碱能药的药物组合物在治疗前驱综合征中的用途,并且涉及一种通过施用这种药物组合物治疗前驱综合征的方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号